Skip to content
You are now leaving to visit

Akcea Reports Financial Results and Highlights for First Quarter 2018

TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDI TM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the company through key milestones in 2019 Conference Call Webcast Thursday, May 3 , 4:30 p.m.